Treatment of UC With Novel Therapeutics

Korábbi kezelés

• Infectious Colitis or drug induced colitis
• Use of rectal therapies

Más betegség

• History of uncontrolled hypertension with systolic BP > 140 and systolic BP > 90
• Crohn's Disease or Indeterminate colitis
• Decompensated liver disease
• Patients who have a confirmed malignancy or cancer within 5 years
• Other comorbidities including: Diabetes mellitus, systemic lupus
• Prohibited medications: Vitamin C, prednisone, immune modulators (including but not limited to azathioprine, 6-mercaptopurine, mycophenolate mofetil, tacrolimus, cyclosporine, thalidomide, interleukin-10, interleukin-11, and Omvoh or mirikizumab-mrkz) and biologics within the past six weeks including anti-TNF agents within the past six weeks, vedolizumab within the past six weeks, ustekinumab Risankizumab), a JAKi (tofacitinib or upadacitinib), or Velsipity (etrasimod) within the past 6 weeks. (The aim is to treat people who are having disease activity and just on mesalamine.)

Laborértékek

• Chronic kidney disease as defined by GFR <55mL/min
• Impaired hepatic function (transaminases elevated > 2.5 x ULN) unless due to PSC
• Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease

Egyéb

• Evidence of C. difficile (Negative test result within 1 month is acceptable)
• Patients who are pregnant or breastfeeding
• Congenital or acquired immunodeficiencies
• High likelihood of colectomy in the next 2 months
• Participation in a therapeutic clinical trial in the preceding 30 days or simultaneously during this trial

• Ability to give consent
• Patients with a confirmed diagnosis of UC for > 3 months
• History of ≥ 15 cm of colonic involvement as confirmed by colonoscopy
• Disease activity based on calprotectin > 200
• Allowed medications: mesalamine and sulfasalazine
• Patients with primary sclerosing cholangitis are eligible to enroll